Discovery and bio-optimization of human antibody therapeutics using the XenoMouse® transgenic mouse platform

Immunological Reviews

Volumn 270, Issue 1, 2016, Pages 51-64

  Foltz, Ian N ^a   Gunasekaran, Kannan ^b   King, Chadwick T ^a  

^a Amgen British Columbia   (Canada)

^b AMGEN INC   (United States)

Author keywords

Antibody therapeutics; Bio optimization; Drug discovery; Monoclonal antibodies; XenoMouse

Indexed keywords

IMMUNOGLOBULIN CLASS; LEAD; MONOCLONAL ANTIBODY; RECOMBINANT ANTIBODY;

ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; EPITOPE MAPPING; HUMAN; HYBRIDOMA; IMMUNIZATION; MEDICAL TECHNOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROCESS DEVELOPMENT; REVIEW; TRANSGENIC MOUSE; ANIMAL; ANTIBODY PRODUCTION; BIOSYNTHESIS; BIOTECHNOLOGY; CHEMISTRY; DRUG DEVELOPMENT; GENETIC ENGINEERING; GENETICS; IMMUNOLOGY; METABOLISM;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY FORMATION; BIOTECHNOLOGY; DRUG DISCOVERY; GENETIC ENGINEERING; HUMANS; HYBRIDOMAS; IMMUNOGLOBULIN ISOTYPES; MICE; MICE, TRANSGENIC;

EID: 84957669521     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12409     Document Type: Review

References (73)

1. Reichert JM. Therapeutic monoclonal antibodies approved or in review in the European Union or United States. Available at: https://www.antibodysociety.org/news/approved_mabs.php. Accessed December 1, 2015.
2. Green LL. Transgenic mouse strains as platforms for the successful discovery and development of human therapeutic monoclonal antibodies. Curr Drug Discov Technol 2014;11:74-84.
3. Chan JC, et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A 2009;106:9820-9825.
4. Rathanaswami P, Richmond K, Manchulenko K, Foltz IN. Kinetic analysis of unpurified native antigens available in very low quantities and concentrations. Anal Biochem 2011;414:7-13.
5. Roskos L, Foltz I, King C, Inventors; Amgen Fremont, Inc, assignee. Antibodies directed to parathyroid hormone (PTH) and uses thereof. US 7288253 B2. October 30, 2007.
6. Foltz I, Gallo M, Cooke K, Ketchem RR, Mehlin C, Inventors; Amgen, Inc, applicant. Anti-hepcidin antibodies and methods of use. WO 2009139822 A1. April 28, 2009.
7. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001;38:17-23.
8. Cohenuram M, Saif MW. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs 2007;18:7-15.
9. Stewart R, et al. Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody. Cancer Immunol Res 2015;3:1052-1062.
10. Lacey DL, et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov 2012;11:401-419.
11. Eberlein C, et al. A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo. Oncogene 2013;32:4406-4416.
12. Pan WJ, et al. Pharmacology of AMG 181, a human anti-alpha4 beta7 antibody that specifically alters trafficking of gut-homing T cells. Br J Pharmacol 2013;169:51-68.
13. Bornstein GG, et al. Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. Invest New Drugs 2010;28:561-574.
14. Boone TC, et al., Inventors; Amgen Inc, applicant. Human CGRP receptor binding proteins. WO 2010075238 A1. December 18, 2009.
15. Bedian V, et al., Inventors; Medimmune Limited, applicant. Anti-cxcr4 antibodies and methods of use. WO 2013013025 A2. July 19, 2012.
16. Yan H, et al. Fully human monoclonal antibodies antagonizing the glucagon receptor improve glucose homeostasis in mice and monkeys. J Pharmacol Exp Ther 2009;329:102-111.
17. Lin FF, et al. Generation and characterization of fully human monoclonal antibodies against human Orai1 for autoimmune disease. J Pharmacol Exp Ther 2013;345:225-238.
18. Coughlin M, et al. Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse. Virology 2007;361:93-102.
19. Foltz IN, et al. Treating diabetes and obesity with an FGF21-mimetic antibody activating the betaKlotho/FGFR1c receptor complex. Sci Transl Med 2012;4:162ra153.
20. DeVries PJ, Ostrow DH, Reilly EB, Green LL, Wieler J, Inventors; Abbott Lab, applicant. Erythropoietin receptor binding antibodies. WO 2004035603 A2. October 14, 2003.
21. Beers C, O'neill JC, Foltz I, Ketchem RR, Piasecki JC, Inventors; Amgen, Inc, applicant. Gitr antigen binding proteins. WO 2015031667 A2. August 28, 2014.
22. Kaplan-Lefko PJ, et al. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol Ther 2010;9:618-631.
23. Armitage RJ, et al., Inventors; Amgen, Inc, applicant. Bcma antigen binding proteins. WO 2014089335 A3. December 5, 2013.
24. Hamblett KJ, et al. AMG 595, an anti-EGFRvIII antibody-drug conjugate, induces potent antitumor activity against EGFRvIII-expressing glioblastoma. Mol Cancer Ther 2015;14:1614-1624.
25. Xiao S, et al., Inventors; Amgen Inc, applicant. Antibody constructs for CDH19 and CD3. WO 2014114800 A1. January 27, 2014.
26. Meininger D, Wittekind M, Delaney JM, Zhou M, Piper DE, Inventors; Amgen, Inc, applicant. Human LCAT antigen binding proteins and their use in therapy. WO 2013086443 A1. December 7, 2012.
27. Elvin P, King C, Rathanaswami P, Inventors; Medimmune Limited, applicant. Targeted binding agents directed to heparanase and uses thereof 463. WO 2010041060 A1. October 7, 2009.
28. Foltz I, et al., Inventors; Google Patents, assignee Binding proteins specific for human matriptase. CA 2592249 C, 2009.
29. Eubanks LM, Ellis BA, Cai X, Schlosburg JE, Janda KD. A human recombinant monoclonal antibody to cocaine: Preparation, characterization and behavioral studies. Bioorg Med Chem Lett 2014;24:4664-4666.
30. Mytych DT, et al. Development and characterization of a human antibody reference panel against erythropoietin suitable for the standardization of ESA immunogenicity testing. J Immunol Methods 2012;382:129-141.
31. Jakobovits A, Amado RG, Yang X, Roskos L, Schwab G. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol 2007;25:1134-1143.
32. Mendez MJ, et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet 1997;15:146-156.
33. Clackson T, Hoogenboom HR, Griffiths AD, Winter G. Making antibody fragments using phage display libraries. Nature 1991;352:624-628.
34. Lonberg N. Human antibodies from transgenic animals. Nat Biotechnol 2005;23:1117-1125.
35. Lee EC, et al. Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery. Nat Biotechnol 2014;32:356-363.
36. Buelow R, Van Schooten W, Platzer J, Inventors; Therapeutic Human Polyclonals, applicant. Humanized immunoglobulin loci. WO 2005007696 A2. July 15, 2004.
37. Osborn MJ, et al. High-affinity IgG antibodies develop naturally in Ig-knockout rats carrying germline human IgH/Igkappa/Iglambda loci bearing the rat CH region. J Immunol 2013;190:1481-1490.
38. Robl JM, Kasinathan P, Sullivan E, Kuroiwa Y, Tomizuka K, Ishida I. Artificial chromosome vectors and expression of complex proteins in transgenic animals. Theriogenology 2003;59:107-113.
39. Moller S, et al. Monitoring the expression of purinoceptors and nucleotide-metabolizing ecto-enzymes with antibodies directed against proteins in native conformation. Purinergic Signal 2007;3:359-366.
40. Percival-Alwyn JL, et al. Generation of potent mouse monoclonal antibodies to self-proteins using T-cell epitope "tags". mAbs 2015;7:129-137.
41. Hrabovska A, Bernard V, Krejci E. A novel system for the efficient generation of antibodies following immunization of unique knockout mouse strains. PLoS ONE 2010;5:e12892.
42. Kohler G, Howe SC, Milstein C. Fusion between immunoglobulin-secreting and nonsecreting myeloma cell lines. Eur J Immunol 1976;6:292-295.
43. Greenfield EA. Antibodies: A Laboratory Manual. 2nd edn. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2014.
44. Kodituwakku AP, Jessup C, Zola H, Roberton DM. Isolation of antigen-specific B cells. Immunol Cell Biol 2003;81:163-170.
45. Price PW, et al. Engineered cell surface expression of membrane immunoglobulin as a means to identify monoclonal antibody-secreting hybridomas. J Immunol Methods 2009;343:28-41.
46. Raeber O, Gazit-Bornstein G, Yang X, Cartlidge SA, Tonge DW, Inventors; MedImmune Limited, assignee. Insulin-like growth factor antibodies and uses thereof. US 7939637 B2. May 10, 2011.
47. Babcook JS, Foltz I, King CT, Palathumpat V, Yang X-D, Inventors; Amgen Fremont, Inc, assignee. Anti-CD45RB antibodies. US 7265212 B2. September 4, 2007.
48. Tabrizi M. Considerations in establishing affinity design goals for development of antibody-based therapeutics. In: Tabrizi M, Bornstein GG, Klakamp SL eds. Development of Antibody-Based Therapeutics. New York: Springer New York, 2012:141-151.
49. Tabrizi M, Bornstein GG, Suria H. Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J 2010;12:33-43.
50. Igawa T, et al. Engineered monoclonal antibody with novel antigen-sweeping activity in vivo. PLoS ONE 2013;8:e63236.
51. Takai N, et al. 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer 2005;104:2701-2708.
52. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989;9:1165-1172.
53. Teillaud JL. Antibody-dependent cellular cytotoxicity (ADCC). eLS 2012:1-8.
54. Doronina SO, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003;21:778-784.
55. Loffler A, et al. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 2000;95:2098-2103.
56. LeSauteur L, Maliartchouk S, Le Jeune H, Quirion R, Saragovi HU. Potent human p140-TrkA agonists derived from an anti-receptor monoclonal antibody. J Neurosci 1996;16:1308-1316.
57. Wilson NS, et al. An Fcgamma receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 2011;19:101-113.
58. White AL, et al. Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. Cancer Cell 2015;27:138-148.
59. Baeuerle PA, Kufer P, Bargou R. BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther 2009;11:22-30.
60. Jia XC, et al. A novel method of multiplexed competitive antibody binning for the characterization of monoclonal antibodies. J Immunol Methods 2004;288:91-98.
61. Papadea C, Check IJ. Human immunoglobulin G and immunoglobulin G subclasses: biochemical, genetic, and clinical aspects. Crit Rev Clin Lab Sci 1989;27:27-58.
62. Thomson C. IgG structure and function. In: Ratcliffe M, ed. Encyclopedia of Immunobiology. 1st edn. Philadelphia, PA: Elsevier, 2016, in press.
63. Jung ST, Kang TH, Kelton W, Georgiou G. Bypassing glycosylation: engineering aglycosylated full-length IgG antibodies for human therapy. Curr Opin Biotechnol 2011;22:858-867.
64. Tiller KE, Tessier PM. Advances in antibody design. Annu Rev Biomed Eng 2015;17:191-216.
65. Lowe D, Dudgeon K, Rouet R, Schofield P, Jermutus L, Christ D. Aggregation, stability, and formulation of human antibody therapeutics. Adv Protein Chem Struct Biol 2011;84:41-61.
66. Monsellier E, Bedouelle H. Improving the stability of an antibody variable fragment by a combination of knowledge-based approaches: validation and mechanisms. J Mol Biol 2006;362:580-593.
67. Wang N, et al. Conserved amino acid networks involved in antibody variable domain interactions. Proteins 2009;76:99-114.
68. Worn A, Pluckthun A. Stability engineering of antibody single-chain Fv fragments. J Mol Biol 2001;305:989-1010.
69. Honegger A. Engineering antibodies for stability and efficient folding. Handb Exp Pharmacol 2008;181:47-68.
70. Jung S, Honegger A, Pluckthun A. Selection for improved protein stability by phage display. J Mol Biol 1999;294:163-180.
71. Zurdo J, et al. Early implementation of QbD in biopharmaceutical development: a practical example. Biomed Res Int 2015;2015:605427.
72. Kannan G, Inventor Amgen Inc, applicant. Method of correlated mutational analysis to improve therapeutic antibodies. WO 2012125495 A3. March 9, 2014.
73. Angell N, Ketchem RK, Daris K, O'Neill JW, Gunasekaran K.Best practices in developability assessments of therapeutic protein candidates in the biopharmaceutical industry. In: Kumar S, Singh SK, eds. Developability of Biotherapeutics Computational Approaches. Boca Raton, FL: CRC Press, 2015:175-194.